265 related articles for article (PubMed ID: 17971769)
1. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia.
Farooqui M; Li Y; Rogers T; Poonawala T; Griffin RJ; Song CW; Gupta K
Br J Cancer; 2007 Dec; 97(11):1523-31. PubMed ID: 17971769
[TBL] [Abstract][Full Text] [Related]
2. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats.
Rezende RM; Paiva-Lima P; Dos Reis WG; Camêlo VM; Bakhle YS; de Francischi JN
Neuropharmacology; 2010 Nov; 59(6):551-7. PubMed ID: 20691196
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Majumder M; Xin X; Liu L; Girish GV; Lala PK
Cancer Sci; 2014 Sep; 105(9):1142-51. PubMed ID: 24981602
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Aerts JG; Hegmans JP
BMC Cancer; 2010 Aug; 10():464. PubMed ID: 20804550
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Gendy AS; Lipskar A; Glick RD; Steinberg BM; Edelman M; Soffer SZ
J Pediatr Surg; 2011 Jan; 46(1):108-14. PubMed ID: 21238650
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.
Barnes NL; Warnberg F; Farnie G; White D; Jiang W; Anderson E; Bundred NJ
Br J Cancer; 2007 Feb; 96(4):575-82. PubMed ID: 17285134
[TBL] [Abstract][Full Text] [Related]
11. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Wang X; Zhang L; O'Neill A; Bahamon B; Alsop DC; Mier JW; Goldberg SN; Signoretti S; Atkins MB; Wood CG; Bhatt RS
Br J Cancer; 2013 Feb; 108(2):319-26. PubMed ID: 23322198
[TBL] [Abstract][Full Text] [Related]
12. [Celecoxib induces apoptosis and inhibits angiogenesis in gastric cancer].
Ran JT; Zhou YN; Tang CW; Lu JR; Wu J; Lu H; Yang GD
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):448-51. PubMed ID: 19024521
[TBL] [Abstract][Full Text] [Related]
13. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats.
Sato H; Bolli R; Rokosh GD; Bi Q; Dai S; Shirk G; Tang XL
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2557-64. PubMed ID: 17704286
[TBL] [Abstract][Full Text] [Related]
14. Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats.
Nishiyama T
Acta Anaesthesiol Scand; 2006 Feb; 50(2):228-33. PubMed ID: 16430547
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Shirode AB; Sylvester PW
Biomed Pharmacother; 2010 May; 64(5):327-32. PubMed ID: 19954924
[TBL] [Abstract][Full Text] [Related]
16. Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.
Tian J; Lambertz I; Berton TR; Rundhaug JE; Kiguchi K; Shirley SH; Digiovanni J; Conti CJ; Fischer SM; Fuchs-Young R
Mol Carcinog; 2012 Dec; 51(12):973-83. PubMed ID: 22006370
[TBL] [Abstract][Full Text] [Related]
17. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Dovizio M; Tacconelli S; Ricciotti E; Bruno A; Maier TJ; Anzellotti P; Di Francesco L; Sala P; Signoroni S; Bertario L; Dixon DA; Lawson JA; Steinhilber D; FitzGerald GA; Patrignani P
J Pharmacol Exp Ther; 2012 Apr; 341(1):242-50. PubMed ID: 22262921
[TBL] [Abstract][Full Text] [Related]
18. Discrepancy between effects of milligram and nanogram doses of a COX-2 inhibitor (celecoxib) on morphine state-dependent memory of passive avoidance in mice.
Khalilzadeh A; Tayebi Meybodi K; Vakili Zarch A; Zarrindast MR; Djahanguiri B
Brain Res Bull; 2005 Nov; 67(6):443-7. PubMed ID: 16216692
[TBL] [Abstract][Full Text] [Related]
19. The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
Awara WM; El-Sisi AE; El-Sayad ME; Goda AE
Pharmacol Res; 2004 Nov; 50(5):487-98. PubMed ID: 15458769
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Sui W; Zhang Y; Wang Z; Wang Z; Jia Q; Wu L; Zhang W
Oncol Rep; 2014 May; 31(5):2252-60. PubMed ID: 24647425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
